Novo Nordisk secures FDA approval of RNAi therapy from $3.3B Dicerna takeovernews2023-10-02T18:57:27+00:00October 2nd, 2023|Endpoints News|
Flagship poaches another pharma R&D leader as GSK’s Lepore heads to ProFoundnews2023-10-02T18:51:00+00:00October 2nd, 2023|Endpoints News|
Biogen nabs FDA approval for its Actemra biosimilar for arthritisnews2023-10-02T18:10:15+00:00October 2nd, 2023|Endpoints News|
Federal judge denies Chamber of Commerce’s effort to block IRA’s Medicare drug price negotiation provisionsnews2023-10-02T17:54:04+00:00October 2nd, 2023|Endpoints News|
Novo Nordisk, Johnson & Johnson, Amgen and Novartis agree to participate in Medicare negotiationsnews2023-10-02T15:57:12+00:00October 2nd, 2023|Endpoints News|
Rocket’s gene therapy gets a PDUFA date; SAB Biotherapeutics’ $130M; Acurix to move to PhIIInews2023-10-02T15:24:14+00:00October 2nd, 2023|Endpoints News|
Novartis to seek accelerated approval for oral complement inhibitor in rare kidney diseasenews2023-10-02T15:12:27+00:00October 2nd, 2023|Endpoints News|
Syros lays off 35% of workers, replaces CEO and loses CSO after axed pactsnews2023-10-02T15:11:38+00:00October 2nd, 2023|Endpoints News|
Q3 snapshot: The IPO market shows fresh signs of improvement, but the biotech crunch continues to bitenews2023-10-02T13:43:43+00:00October 2nd, 2023|Endpoints News|
Providence launches Praia Health to help health systems maintain patient relationshipsnews2023-10-02T12:00:50+00:00October 2nd, 2023|Endpoints News|
